Publication:
Pretreatment HALP score and survival outcomes in patients with metastatic renal cell carcinoma receiving first-line tyrosine kinase inhibitors: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Simple item page
dc.contributor.coauthorGünaltılı, M.
dc.contributor.coauthorBölek, H.
dc.contributor.coauthorKaplan Tüzün, E.
dc.contributor.coauthorUsta, S.
dc.contributor.coauthorEfil, S. C.
dc.contributor.coauthorAkkus, A. F.
dc.contributor.coauthorIşık, S.
dc.contributor.coauthorKapar, C.
dc.contributor.coauthorSekmek, S.
dc.contributor.coauthorGüzel, H. G.
dc.contributor.coauthorGuliyev, M.
dc.contributor.coauthorOzudogru, T.
dc.contributor.coauthorGöksu, S. S.
dc.contributor.coauthorSever, Ö. N.
dc.contributor.coauthorArslan, Ç.
dc.contributor.coauthorKaradurmuş, N.
dc.contributor.coauthorSendur, M. A. N.
dc.contributor.coauthorÖzgüroğlu, M.
dc.contributor.coauthorYekedüz, E.
dc.contributor.coauthorÜrün, Y.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorTural, Deniz
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2026-07-22T13:08:47Z
dc.date.issued2026
dc.description.abstractThe hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been investigated as an immunonutritional biomarker in several solid tumors; however, data in metastatic renal cell carcinoma (mRCC) remain limited. This study aimed to evaluate the prognostic significance of the pretreatment HALP score in patients with mRCC receiving first-line tyrosine kinase inhibitor (TKI) therapy. Methods: A multicenter retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. HALP was calculated as hemoglobin (g/dL) × albumin (g/dL) × lymphocyte count (×109/L)/platelet count (×109/L). Patients were categorized into HALP-low and HALP-high groups according to the cohort median HALP value. Results: A total of 1001 patients were enrolled. The median time to treatment failure (TTF) was significantly shorter in the HALP-low group than in the HALP-high group (7.43 months [95% CI 6.4–8.5] vs. 14.26 months [95% CI 12.1–16.4], p
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.ScopusPercentile84
dc.identifier.ScopusQuartileQ1
dc.identifier.WoSPercentile72.5
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.3390/cancers18132127
dc.identifier.embargoN/A
dc.identifier.issn2072-6694
dc.identifier.issue13
dc.identifier.pubmed42449669
dc.identifier.scopus2-s2.0-105044657547
dc.identifier.urihttp://doi.org/10.3390/cancers18132127
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33793
dc.identifier.volume18
dc.identifier.wos001818912000001
dc.keywordsMetastatic renal cell carcinoma
dc.keywordsTyrosine kinase inhibitor
dc.keywordsHALP score
dc.keywordsOverall survival
dc.keywordsTime to treatment failure
dc.languageeng
dc.publisherMDPI
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofCancers
dc.subjectHealth sciences
dc.subjectMedicine
dc.subjectOncology
dc.subjectPulmonary and respiratory medicine
dc.titlePretreatment HALP score and survival outcomes in patients with metastatic renal cell carcinoma receiving first-line tyrosine kinase inhibitors: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files

Collections

Publications without Fulltext